On Friday, BofA Securities maintained an Underperform rating on shares of Hims & Hers Health, Inc. (NYSE:HIMS) with a steady price target of $18.00.
The firm expressed ongoing concerns about the future of the company's compounded GLP-1 products due to aggressive defense tactics by pharmaceutical manufacturers. These concerns come even as HIMS demonstrates solid financial health, with InvestingPro analysis showing a healthy current ratio of 2.14 and minimal debt levels.
The analyst from BofA Securities highlighted recent actions by Novo Nordisk (NYSE:NVO), a major pharmaceutical company, which could impact Hims & Hers' strategy. Last week, Novo Nordisk submitted a Citizen Petition to the FDA, seeking to restrict compounding pharmacies from producing generic versions of its diabetes drug Victoza, known generically as liraglutide.
This move by Novo Nordisk came after the Outsourcing Facilities Association nominated liraglutide for inclusion on the 503B Bulks List, which is a register of drug substances approved for compounding. The analyst emphasized the importance of following any forthcoming decisions from the FDA, as these could potentially limit Hims & Hers' ability to launch their compounded versions of liraglutide.
Hims & Hers, which is planning to introduce liraglutide in 2025, may face additional risks to their GLP-1 portfolio expansion strategy if further compounding restrictions are imposed. The company's anticipated product launches hinge on the ability to compound these substances, which are now under scrutiny.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.